| Not Yet Recruiting | RE and Probiotics in MAFLD/NAFLD NCT06563921 | Nicolaus Copernicus University | N/A |
| Recruiting | Trial of CS060380 Tablets for Non-alcoholic Steatohepatitis (NASH) NCT07198386 | Cascade Pharmaceuticals, Inc | Phase 2 |
| Withdrawn | Digital Therapeutic Lifestyle Intervention Program for Patients With MASLD NCT06352177 | Milton S. Hershey Medical Center | N/A |
| Recruiting | Digoxin In NASH (CODIN) NCT06588699 | Yale University | Phase 2 |
| Recruiting | Evaluation of Non-Invasive Tests for Metabolic Liver Disease NCT07122700 | Foundation for the National Institutes of Health | — |
| Withdrawn | A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASLD and MASH NCT06692283 | Sagimet Biosciences Inc. | Phase 3 |
| Withdrawn | A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASH and F2/F3 Fibrosis NCT06594523 | Sagimet Biosciences Inc. | Phase 3 |
| Recruiting | Secondary and Tertiary Digital Prevention of Non-alcoholic and Dysmetabolic Liver Disease NCT06879236 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | — |
| Recruiting | Optimizing Noninvasive assessMent Of DysmEtabolic Compensated Advanced Liver Disease NCT06888310 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | N/A |
| Recruiting | To Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BAR502 in Healthy Subjects NCT06705998 | BAR Pharmaceuticals s.r.l. | Phase 1 |
| Not Yet Recruiting | Precise Evaluation Criteria for Histological Regression of NASH Fibrosis NCT06364462 | Beijing Friendship Hospital | — |
| Active Not Recruiting | A Study to Evaluate DD01 in Overweight/Obese Subjects With MASLD/MASH NCT06410924 | Neuraly, Inc. | Phase 2 |
| Unknown | Early Liver Disease Breath Detection NCT05935488 | Owlstone Ltd | — |
| Active Not Recruiting | A Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of VSA006 in Chinese NASH Patients NCT06322628 | Visirna Therapeutics HK Limited | Phase 2 |
| Completed | ALG-055009 in Non-cirrhotic Adults With MASH (HERALD) NCT06342947 | Aligos Therapeutics | Phase 2 |
| Active Not Recruiting | An Imaging-based Quantitative Biomarker Assay for NAFLD in Children NCT06354491 | University of Wisconsin, Madison | N/A |
| Recruiting | The Impact of Different Carbohydrate Restriction After a Gastric Bypass on the Ketosis and Ketoacidosis NCT06338969 | The Society of Bariatric and Metabolic Surgeons of Kazakhstan | N/A |
| Unknown | A Multicenter, Double-blind, Placebo-randomized Controlled Clinical Study on the Treatment of Non-alcoholic St NCT06193629 | Shupei Li | N/A |
| Completed | Feasibility, Safety and Acceptability of a Mobile Health Delivered Exercise Training Program in Patients With NCT06195943 | Milton S. Hershey Medical Center | N/A |
| Recruiting | Androgens and NAFLD Longitudinal Cohort Study NCT06124261 | University of California, San Francisco | — |
| Withdrawn | Assessment of Fatty Liver With Thermo-acoustic Device NCT04302051 | Medical College of Wisconsin | — |
| Active Not Recruiting | Effects of Phytosterol Supplementation on Liver Function and Inflammatory Status in Patients with Nonalcoholic NCT06697977 | University of Jordan | N/A |
| Unknown | Psoriasis and Non Alcoholic Steatohepatitis: Is There a Shared Inflammatory Network ? NCT05994677 | Assiut University | — |
| Not Yet Recruiting | Study Consortium for Evaluation of RNPC Program in Obese and Overweight Patients (SCOOP-RNPC) NCT05857319 | Groupe Éthique et Santé | — |
| Completed | A Clinical Trial of BGT-002 Tablets in Subjects With Nonalcoholic Steatohepatitis NCT06491576 | Burgeon Therapeutics Co., Ltd. | Phase 1 / Phase 2 |
| Completed | Study to Determine the Response to COVID-19 Vaccination and Prevalence of COVID-19 in Subjects With Chronic Li NCT05669677 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | — |
| Unknown | Phase Ib/II Study to Evaluate the Efficacy and Safety of GH509 Versus Placebo in Patients With NASH/NAFLD NCT05784779 | 1Globe Biomedical Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | HuHuangLianzonggan Capsule in Subjects With Nonalcoholic Steatohepatitis: a Phase 2 tRial(HHL-HEPAR) NCT05632861 | Tasly Pharmaceutical Group Co., Ltd | Phase 2 |
| Active Not Recruiting | Study to Evaluate the Efficacy and Safety of K-877-ER and CSG452 in Participants With NASH With Liver Fibrosis NCT05327127 | Kowa Research Institute, Inc. | Phase 2 |
| Completed | Effect of Dipeptidyl Peptidase- 4 Inhibitors on Non-Alcoholic Steatohepatitis and Type 1 Diabetes NCT06348706 | Ain Shams University | Phase 3 |
| Active Not Recruiting | A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NA NCT05500222 | Madrigal Pharmaceuticals, Inc. | Phase 3 |
| Completed | Knockdown of HSD17B13 mRNA, Pharmacokinetics, Safety, and Tolerability, of AZD7503 in Non-Alcoholic Fatty Live NCT05560607 | AstraZeneca | Phase 1 |
| Completed | Misoprostol for NASH NCT05804305 | Ziauddin University | Phase 2 |
| Completed | The Visceral Adiposity Measurement and Observation Study NCT05383456 | Theratechnologies | — |
| Completed | A Phase II Clinical Trial of Chiglitazar for NASH NCT05193916 | Chipscreen Biosciences, Ltd. | Phase 2 |
| Completed | Phase 1 Study to Evaluate the Safety and Tolerability of VK2735 NCT05203237 | Viking Therapeutics, Inc. | Phase 1 |
| Recruiting | Role of the Very Low Calorie Ketogenic Diet (VLCKD) in Patients With Non-Alcoholic Steatohepatitis (NASH) With NCT06308757 | University of Bologna | N/A |
| Completed | Effects of Online App Weight Loss Programs on Liver Health in Obese Adults NCT05015491 | Noom Inc. | N/A |
| Completed | Screening of Liver Fibrosis Using Blood Tests in Patients With Type 2 Diabetes Mellitus NCT04232293 | Nantes University Hospital | N/A |
| Not Yet Recruiting | THE FRENCH NATIONAL NAFLD COHORT (FRench pAtients With MEtabolic Steatosis) NCT04925362 | Assistance Publique - Hôpitaux de Paris | N/A |
| Unknown | Plant Stanols and Liver Inflammation in Overweight and Obese Children NCT04783116 | Maastricht University Medical Center | N/A |
| Unknown | Study to Evaluate MET409 Alone or in Combination With Empagliflozin in Patients With Type 2 Diabetes and NASH NCT04702490 | Metacrine, Inc. | Phase 2 |
| Terminated | A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) NCT04565717 | Alnylam Pharmaceuticals | Phase 1 |
| Unknown | Hyperpolarized Pyruvate (13C) Magnetic Resonance Imaging In Patients With Fatty Liver Disease NCT06176079 | Michael Ohliger, MD PhD | — |
| Completed | An Open-Label, Two-Part Study Designed to Assess the Absolute Bioavailability and Mass Balance of Aramchol NCT05874336 | Galmed Pharmaceuticals Ltd | Phase 1 |
| Active Not Recruiting | LITMUS Imaging Study NCT05479721 | University of Oxford | — |
| Withdrawn | Validation of the LiverFASt Test and the Associated Fibrosis Staging Scores Compared to Liver Tissue Pathology NCT03980912 | Fibronostics USA, Inc | — |
| Completed | A Multiple Ascending Dose Study of Pegozafermin in Participants With Biopsy Confirmed Nonalcoholic Steatohepat NCT04048135 | 89bio, Inc. | Phase 1 / Phase 2 |
| Completed | A Phase 2 Study of Elobixibat in Adults With NAFLD or NASH NCT04006145 | Albireo | Phase 2 |
| Active Not Recruiting | DIAbetes and NAFLD NCT06315361 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | — |
| Recruiting | Evaluation of Risk of hEpatocellular Carcinoma NCT06523179 | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | N/A |
| Completed | A Study of EDP-305 in Subjects With Mild and Moderate Hepatic Impairment Compared With Normal Healthy Voluntee NCT03207425 | Enanta Pharmaceuticals, Inc | Phase 1 |
| Completed | Drug-drug Interaction Study Between EDP-305, Midazolam, Caffeine and Rosuvastatin in Healthy Volunteers. NCT03187496 | Enanta Pharmaceuticals, Inc | Phase 1 |
| Completed | Efficacy and Safety of MT-3995 in Patients With Non-Alcoholic Steatohepatitis(NASH) NCT02923154 | Tanabe Pharma Corporation | Phase 2 |
| Recruiting | The European NAFLD Registry NCT04442334 | Newcastle University | — |
| Withdrawn | Natural Soybean-derived Femarelle ®for Patients With Non Alcoholic Fatty Liver Disease NCT01269320 | Hadassah Medical Organization | Phase 4 |